Brian F. Volkman

This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.

This study engineers orthogonal chemokine-receptor pairs to enable targeted immune cell migration and collective swarming behavior in engineered T cells.

The paper uses AlphaFold to identify gating residues that control conformational accessibility in proteins, finding that AlphaFold sometimes misapplies this principle.

This paper identifies allele-specific resistance mechanisms to daraxonrasib in pancreatic cancer and demonstrates how these guide effective salvage therapies.

This study reveals an unconventional activation mechanism of the atypical GPCR ACKR3 using engineered nanobodies and cryo-EM, showing that extracellular pocket volume changes, not microswitch conformational shifts, drive receptor activity.

This study uses inverse agonistic nanobodies to reveal constitutive activity of ACKR3, showing it drives non-canonical signaling and basal cell motility, suggesting therapeutic potential.

This paper classifies EHMT1 variants into structural, dynamic, and combined structural-dynamic categories using computational methods to improve variant interpretation for Kleefstra syndrome.

The paper uses molecular dynamics simulations to analyze 86 KRAS mutations, revealing mutation-specific conformations and functional insights not captured by current genomic tools.